url:https://finance.yahoo.com/news/regeneron-beats-quarterly-profit-estimates-103455264.html
title:Regeneron_beats_quarterly_profit_estimates_on_eczema_treatment_strength
Nov 2 (Reuters) - Regeneron Pharmaceuticals on Thursday beat Wall Street estimates for third-quarter profit, driven by strong demand for its eczema treatment Dupixent.
On adjusted basis, the company reported a profit of $11.59 per share for the quarter, above analysts' estimates of $10.72, according to LSEG data. (Reporting by Sriparna Roy in Bengaluru; Editing by Maju Samuel)